Atea Pharmaceuticals Inc (AVIR) - News Archive

Atea Pharmaceuticals Inc. is poised to illuminate the ongoing challenges faced by patients with Hepatitis C Virus (HCV) through an engaging virtual Key Opinion Leader (KOL) panel scheduled for May 14, 2025. This crucial...

Atea Pharmaceuticals Implements Strategic Initiatives to Bolster Shareholder ValueAtea Pharmaceuticals Inc. (Nasdaq: AVIR), a pioneering clinical-stage biopharmaceutical company focused on developing oral antiviral ther...

Atea Pharmaceuticals Explores Strategic Partnerships Amidst Financial Challenges Atea Pharmaceuticals, a clinical-stage company listed on Nasdaq under the ticker AVIR, is setting its sights on strategic growth amidst a...

Summary of Atea Pharmaceuticals’ Recent DevelopmentsAtea Pharmaceuticals, Inc. a prominent clinical-stage biopharmaceutical company focused on developing oral antiviral therapeutics, has recently released updates relate...

Innovative Horizons: The Unveiling of Bemnifosbuvir s Metabolic Secrets Amid Atea Pharmaceuticals Financial Struggle In the relentless pursuit of innovative medical therapies, the journey is often marked by groundbreaki...

Atea Pharmaceuticals: Promising Results for Bemnifosbuvir and Ruzasvir Combination in Hepatitis C Treatment, as Company Makes Strides in COVID-19 ResearchAtea Pharmaceuticals, a leading biopharmaceutical company, has re...

Hepatitis C virus (HCV) is a major global health concern, with an estimated 71 million people worldwide living with chronic HCV infection. This blood-borne virus can lead to severe liver damage, cirrhosis, and even hepa...

Headquartered in Boston, Massachusetts, Atea specializes in antiviral therapeutics, pushing the boundaries of scientific innovation to meet the dire need in the market for efficacious treatments against grave viral dise...

Atea Pharmaceuticals has recently reported the completion of patient enrollment in the Phase-3 SUNRISE-3 Trial of Bemnifosbuvir, an oral antiviral medication developed for the treatment of high-risk COVID-19 patients. T...

Atea Pharmaceuticals, a biopharmaceutical company focused on discovering and developing antiviral therapeutics, recently announced positive initial data from a Phase 2 study for Hepatitis C Virus (HCV) and a significant...